Reese Marketos played the role of government prosecutor in a False Claims Act case about alleged off-label use of an HIV drug ...

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals ...

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.

The Dark Secrets of Johnson & Johnson.” Gardiner Harris, a former pharmaceutical reporter for The New York Times and a reporter for The Wall Street Journal, effectively explains the legal battles ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. The chief executive of Johnson & Johnson has warned that potential US tariffs on the pharmaceutical ...

President Trump unveiled a wide-ranging executive order that aims to lower drug prices, boost transparency into fees charged ...

Q1 adjusted EPS of $2.77 beat estimates; cancer drug Darzalex sales jumped 20.3% ... % or 4.2 operationally to $13.90 billion. Also Read: Johnson & Johnson, Protagonist Tout Positive Results ...

(Reuters) -Johnson & Johnson Chief Executive Joaquin ... to mitigate supply chain vulnerabilities and prevent any drug shortages that can result from tariffs. J&J is the first major healthcare ...